Blueprint
 
 
 
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 20 February 2018
 
GlaxoSmithKline plc
(Name of registrant)

 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

 
 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

 
 
 
Yes      No x
 
 
GlaxoSmithKline plc (the 'Company')
Shares sold to meet tax liabilities
 
Following the vesting of the pre-tax awards granted in 2015 under the GlaxoSmithKline Deferred Annual Bonus Plan ('DABP') on 15 February 2018 and as notified on 16 February 2018, the notifications that follow reflect change in the interests of the Person Discharging Managerial Responsibilities ('PDMRs') in American Depositary Shares ('ADS') of the Company arising from the sale of ADSs to meet tax liabilities.
 
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial  instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
 
 
 
 
 
 
b)
Nature of the transaction
The sale of ADSs to meet tax liabilities further to the vesting of awards granted in 2015 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.
 
 
c)
Price(s) and volume(s)
 Price(s)
 Volume(s)
 $37.4803
 3,480 (Deferred)
 $37.4803
 2,520 (Matching)
d)
Aggregated information
Aggregated volume Price
  6,000
  $37.4803
e)
Date of the transaction
2018-02-16
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: February 20, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc